Comparision of the effectiveness of combined therapy sodium-glucose transporter 2 inhibitors versus traditional therapy in treatment of type 2 diabetes with heart failure in Hai Phong International General Hospital

Abstract

To compare the effectiveness of a combination therapy involving sodium-glucose co-transporter 2 (SGLT2i) inhibitors with traditional therapy in treating type 2 diabetes mellitus (T2DM) accompanied by heart failure, the research team conducted a retrospective study on 106 medical records, including 53 patients treated with traditional therapy and 53 patients treated with combination therapy. This study aimed to achieve two objectives: comparing the effectiveness of the SGLT2i combination therapy against the traditional therapy in treating T2DM with concurrent heart failure. After 3 months of treatment, both patient groups showed a reduction in HbA1C, with the traditional therapy group showing a decrease of 0.71% and the SGLT2i group showing a decrease of 0.72%. This difference was not statistically significant (p > 0.05). Similarly, the percentage of patients achieving the target HbA1C and fasting plasma glucose levels increased in both groups, with the SGLT2i group experiencing a greater increase, although the difference was not statistically significant (p > 0.05). The mean BNP levels also decreased in both groups, with a greater reduction in the SGLT2i group (12.54 pg/mL) compared to the traditional group (7.07 pg/mL); however, this difference was not statistically significant (p > 0.05). Notably, the weight reduction in the SGLT2i group (1.25 kg) was significantly more than in the traditional therapy group (0.44 kg), and this difference was statistically significant (p < 0.05). Overall, the results indicate that the SGLT2i combination therapy offers some benefits over traditional therapy, but the differences in treatment effectiveness between the two groups were not statistically significant for most parameters.